Brief: Enveric Biosciences Reports Results From Preclinical Studies Of Lead Candidate Eb-373
24/07/2023 13:43
July 24 (Reuters) - Enveric Biosciences Inc ENVB.O :
* ENVERIC BIOSCIENCES REPORTS POSITIVE RESULTS FROM
PRECLINICAL
STUDIES SUPPORTING METABOLIC PROFILE OF LEAD CANDIDATE EB-373
* ENVERIC BIOSCIENCES - INTENDS TO PRESENT THOROUGH ANALYSES
OF
PRECLINICAL ADME AND TOXICOLOGY STUDIES FOR EB-373 AT A FUTURE
SCIENTIFIC CONFERENCE
Source text for Eikon: ID:nBw1x56gQa
Further company coverage: ENVB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enveric Biosciences
See all newsBrief: Enveric Biosciences Announces Positive Results From IND-Enabling ADMET Studies
Enveric Biosciences Q2 net loss widens
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer
Brief: Enveric Biosciences Initiates Investigational New Drug (IND)-Enabling Genotoxicity Studies Of Lead Neuroplastogen Candidate EB-003
Brief: Enveric Biosciences Reports Positive Preclinical Results From Phototoxicity Analysis For Lead Neuroplastogen Candidate Eb-003